This is a preview of subscription content, log in via an institution to check access.
Notes
ICER's HBPB is a price range suggesting the highest US price a manufacturer should charge for a treatment, based on the amount of improvement in overall health patients receive from that treatment.
Reference
Institute for Clinical and Economic Review (ICER). ICER Publishes Evidence Report on Treatments for Myasthenia Gravis. Internet Document : 14 Sep 2021. Available from: URL: https://icer.org/news-insights/press-releases/icer-publishes-evidence-report-on-treatments-for-myasthenia-gravis/
Rights and permissions
About this article
Cite this article
ICER: eculizumab and efgartigimod currently too expensive to be cost effective for myasthenia gravis. PharmacoEcon Outcomes News 887, 30 (2021). https://doi.org/10.1007/s40274-021-08046-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08046-0